Statement of Need
Atopic dermatitis (AD), a severe form of eczema and intense pruritus, is associated with a substantial and multifaceted patient-reported burden that encompasses sleep disturbances, anxiety, depression, reduced function/productivity, and impaired quality of life. The incidence of AD is high, estimated to be approximately 15%-20% in children and 1%-3% in adults worldwide (Yong & Tay, 2017). Population studies within the United States have shown that AD disproportionately affects Black Americans compared with other ethnic groups (Brunner & Guttman-Yassky, 2019). Black Americans are more likely to experience severe disease and less favorable treatment outcomes (Kaufman et al, 2019). In this activity, Dr. Shawn Kwatra and Dr. Linda Stein Gold will direct thoughtful consideration of the health care disparities faced by Black patients with AD, best practices in diagnosis and assessment, and the applicability of novel therapeutic approaches for moderate-to-severe disease.
Dermatologists, primary care physicians, nurse practitioners, physician assistants, pharmacists, nurses, and other health care professionals involved in the treatment of patients with atopic dermatitis (AD).
Shawn Kwatra, MD (Chairperson)
Director, John Hopkins Itch Center
Associate Professor of Dermatology
John Hopkins University School of Medicine
Linda F. Stein Gold, MD
Director of Dermatology Clinical Research
Division Head of Dermatology
Henry Ford Health System
There is no fee to participate in or claim CME/NCPD/CPE credit for this activity.
i3 Health is accredited by the American Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
i3 Health designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 Medical Knowledge and Practice Assessment points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 0.5 hours of Category 1 credit for completing this program.
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Nursing Continuing Professional Development
i3 Health is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
A maximum of 0.5 contact hours may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.4 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 0.5 contact hours.
Continuing Pharmacy Education
St. John Fisher University Wegmans School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0584-9999-21-028-H01-P is eligible for 0.5 ACPE CE hours.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES
i3 Health and St. John Fisher University Wegmans School of Pharmacy (WSOP) endorse the standards of the ACCME, ACPE, and ANCC that require everyone in a position to control the content of a CME/NCPD/CPE activity to disclose all financial relationships with commercial interests that are related to the content of the CME/NCPD/CPE activity. CME/NCPD/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME/NCPD/CPE content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health and St. John Fisher University Wegmans School of Pharmacy (WSOP) will identify, review, and mitigate all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health and St. John Fisher University Wegmans School of Pharmacy (WSOP) do not endorse any products or services.
Relevant financial relationships exist between the following individuals and commercial interests:
The i3 Health planners, reviewers, and managers have nothing to disclose.
St. John Fisher University Wegmans School of Pharmacy (WSOP) staff members have no relevant financial relationships to disclose.
Shawn Kwatra, MD, discloses that he has served on an advisory board or panel for AbbVie, Galderma, Incyte, Pfizer, and Sanofi; that he has served as a consultant for AbbVie, Arcutis, ASLAN, Celldex, Galderma, Genzada, Incyte, Johnson & Johnson, Novartis, Pfizer, and Regeneron; and that he has received grants or research support from Galderma, Pfizer, and Sanofi.
Linda F. Stein Gold, MD, discloses that she has served on an advisory board or panel for Arcutis, Dermavant, Galderma, Incyte, LEO, Lilly, Pfizer, and Regeneron; that she has served on a speaker’s bureau for Arcutis, Dermavant, Galderma, Incyte, LEO, Lilly, Pfizer, Regeneron, and Sanofi; that she has served as a consultant for Arcutis, Dermavant, Galderma, Incyte, LEO, Lilly, Pfizer, Regeneron, and Sanofi; and that she has received grants/research support: Arcutis, Dermavant, Incyte, Leo, and Pfizer.
i3 Health has mitigated all relevant financial relationships.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.
UNAPPROVED USE DISCLOSURE
i3 Health and St. John Fisher University Wegmans School of Pharmacy (WSOP) require CME/NCPD/CPE faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
The information provided at this CME/NCPD/CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a health care provider relative to diagnostic and treatment options of a specific patient’s medical condition.
This activity is supported by independent educational grants provided by Incyte, Sanofi, and Regeneron Pharmaceuticals.
Aggregate participant data will be shared with commercial supporters of this activity.